Cargando…

Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children

Many medicines are used “off‐label” in children outside the terms of the license. Feasible pediatric clinical trials are a challenge to design. Conect4children (c4c) is an Innovative Medicines Initiative project to set up a pan‐European pediatric clinical trial network aiming to facilitate the devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Katharine, Mahler, Fenna, Lutsar, Irja, Nafria Escalera, Begonya, Breitenstein, Stefanie, Vassal, Gilles, Claverol, Joana, Noel Palacio, Nuria, Portman, Ron, Pope, Gavin, Bakker, Martijn, van der Geest, Tessa, Turner, Mark A., de Wildt, Saskia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014692/
https://www.ncbi.nlm.nih.gov/pubmed/36510699
http://dx.doi.org/10.1111/cts.13459
_version_ 1784907050660134912
author Cheng, Katharine
Mahler, Fenna
Lutsar, Irja
Nafria Escalera, Begonya
Breitenstein, Stefanie
Vassal, Gilles
Claverol, Joana
Noel Palacio, Nuria
Portman, Ron
Pope, Gavin
Bakker, Martijn
van der Geest, Tessa
Turner, Mark A.
de Wildt, Saskia N.
author_facet Cheng, Katharine
Mahler, Fenna
Lutsar, Irja
Nafria Escalera, Begonya
Breitenstein, Stefanie
Vassal, Gilles
Claverol, Joana
Noel Palacio, Nuria
Portman, Ron
Pope, Gavin
Bakker, Martijn
van der Geest, Tessa
Turner, Mark A.
de Wildt, Saskia N.
author_sort Cheng, Katharine
collection PubMed
description Many medicines are used “off‐label” in children outside the terms of the license. Feasible pediatric clinical trials are a challenge to design. Conect4children (c4c) is an Innovative Medicines Initiative project to set up a pan‐European pediatric clinical trial network aiming to facilitate the development of new medicines for children. To optimize pediatric trial development by promoting innovative trial design, c4c set up a European multidisciplinary advice service, including the voice of young patients and families, tailored to industry and academia. A network of experts was established to provide multidisciplinary advice to trial sponsors. Experts were selected to join clinical and innovative methodology expert groups. A patient and public involvement (PPI) database, to include the expert opinion of patients and parents/carers was formed. A stepwise process was developed: (1) sponsors contact c4c, (2) scoping interview takes place, (3) ad hoc advice group formed, (5) advice meeting held, and (6) advice report provided. Feedback on the process was collected. Twenty‐four clinical and innovative methodology expert groups (>400 experts) and a PPI database of 135 registrants were established. As of September 30, 2022, 36 advice requests were received, with 25 requests completed. Clinical and methodology experts and PPI representatives participated in several advice requests. Sponsors appreciated the advice quality and the multidisciplinary experts from different countries, including experts not known before. Experts and PPI participants were generally satisfied with the process. The c4c project has shown successful proof of concept for a service that presents a new framework to plan innovative and feasible pediatric trials.
format Online
Article
Text
id pubmed-10014692
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100146922023-03-16 Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children Cheng, Katharine Mahler, Fenna Lutsar, Irja Nafria Escalera, Begonya Breitenstein, Stefanie Vassal, Gilles Claverol, Joana Noel Palacio, Nuria Portman, Ron Pope, Gavin Bakker, Martijn van der Geest, Tessa Turner, Mark A. de Wildt, Saskia N. Clin Transl Sci Research Many medicines are used “off‐label” in children outside the terms of the license. Feasible pediatric clinical trials are a challenge to design. Conect4children (c4c) is an Innovative Medicines Initiative project to set up a pan‐European pediatric clinical trial network aiming to facilitate the development of new medicines for children. To optimize pediatric trial development by promoting innovative trial design, c4c set up a European multidisciplinary advice service, including the voice of young patients and families, tailored to industry and academia. A network of experts was established to provide multidisciplinary advice to trial sponsors. Experts were selected to join clinical and innovative methodology expert groups. A patient and public involvement (PPI) database, to include the expert opinion of patients and parents/carers was formed. A stepwise process was developed: (1) sponsors contact c4c, (2) scoping interview takes place, (3) ad hoc advice group formed, (5) advice meeting held, and (6) advice report provided. Feedback on the process was collected. Twenty‐four clinical and innovative methodology expert groups (>400 experts) and a PPI database of 135 registrants were established. As of September 30, 2022, 36 advice requests were received, with 25 requests completed. Clinical and methodology experts and PPI representatives participated in several advice requests. Sponsors appreciated the advice quality and the multidisciplinary experts from different countries, including experts not known before. Experts and PPI participants were generally satisfied with the process. The c4c project has shown successful proof of concept for a service that presents a new framework to plan innovative and feasible pediatric trials. John Wiley and Sons Inc. 2022-12-12 /pmc/articles/PMC10014692/ /pubmed/36510699 http://dx.doi.org/10.1111/cts.13459 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Cheng, Katharine
Mahler, Fenna
Lutsar, Irja
Nafria Escalera, Begonya
Breitenstein, Stefanie
Vassal, Gilles
Claverol, Joana
Noel Palacio, Nuria
Portman, Ron
Pope, Gavin
Bakker, Martijn
van der Geest, Tessa
Turner, Mark A.
de Wildt, Saskia N.
Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title_full Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title_fullStr Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title_full_unstemmed Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title_short Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
title_sort clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014692/
https://www.ncbi.nlm.nih.gov/pubmed/36510699
http://dx.doi.org/10.1111/cts.13459
work_keys_str_mv AT chengkatharine clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT mahlerfenna clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT lutsarirja clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT nafriaescalerabegonya clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT breitensteinstefanie clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT vassalgilles clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT claveroljoana clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT noelpalacionuria clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT portmanron clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT popegavin clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT bakkermartijn clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT vandergeesttessa clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT turnermarka clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT dewildtsaskian clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children
AT clinicalmethodologyandpatientcarerexpertadviceinpediatricdrugdevelopmentbyconect4children